This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Inclusion Criteria

• •Signed Informed Consent Form
• •Male or female, 18 \~75years of age
• •Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1
• •Histologically or cytologically confirmed ES-SCLC
• •No prior treatment for ES-SCLC
• •Measurable disease, as defined by RECIST v1.1
• •Adequate hematologic and end organ function.
• •Serum pregnancy test in screening period for women of childbearing potential should be negative.Except for women who have a history of sterilization or are postmenopausal.Men or woman subjects of reproductive age and their partners must agree to use effective contraception for at least 6 months from the date of signing the Informed Consent Form(ICF) until the last dose of the investigational therapy.